scispace - formally typeset
J

Jose Angel Arranz

Researcher at Hospital General Universitario Gregorio Marañón

Publications -  51
Citations -  3305

Jose Angel Arranz is an academic researcher from Hospital General Universitario Gregorio Marañón. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 17, co-authored 43 publications receiving 2289 citations. Previous affiliations of Jose Angel Arranz include Copenhagen University Hospital.

Papers
More filters
Journal ArticleDOI

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, +18 more
- 01 Mar 2017 - 
TL;DR: Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma.
Journal ArticleDOI

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, +206 more
- 01 Dec 2020 - 
TL;DR: The overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab ( a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma was assessed.
Journal ArticleDOI

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Thomas Powles, +245 more
- 01 Jul 2021 - 
TL;DR: In this paper, the authors assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.
Journal ArticleDOI

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

Jesús García-Donas, +15 more
- 01 Nov 2011 - 
TL;DR: Polymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability, and should promote interventional studies testing alternative therapeutic approaches for patients with such variants.
Journal ArticleDOI

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Brian I. Rini, +11 more
- 01 Nov 2013 - 
TL;DR: The greater proportion of patients in the axitinib titration group achieving an objective response supports the concept of individual axit inib dose titration in selected patients with metastatic renal-cell carcinoma.